Uveal Melanoma Cells Use Ameboid and Mesenchymal Mechanisms of Cell Motility Crossing the Endothelium

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2021 Jan 6

PMID 33405963

Citations 6

Authors

Michael D Onken

Kendall J Blumer

John A Cooper

Affiliations

Soon will be listed here.

Abstract

Uveal melanomas (UMs) are malignant cancers arising from the pigmented layers of the eye. UM cells spread through the bloodstream, and circulating UM cells are detectable in patients before metastases appear. Extravasation of UM cells is necessary for formation of metastases, and transendothelial migration (TEM) is a key step in extravasation. UM cells execute TEM via a stepwise process involving the actin-based processes of ameboid blebbing and mesenchymal lamellipodial protrusion. UM cancers are driven by oncogenic mutations that activate Gαq/11, and this activates TRIO, a guanine nucleotide exchange factor for RhoA and Rac1. We found that pharmacologic inhibition of Gαq/11 in UM cells reduced TEM. Inhibition of the RhoA pathway blocked amoeboid motility but led to enhanced TEM; in contrast, inhibition of the Rac1 pathway decreased mesenchymal motility and reduced TEM. Inhibition of Arp2/3 complex allowed cells to transmigrate without intercalation, a direct mechanism similar to the one often displayed by immune cells. BAP1-deficient (+/-) UM subclones displayed motility behavior and increased levels of TEM, similar to the effects of RhoA inhibitors. We conclude that RhoA and Rac1 signaling pathways, downstream of oncogenic Gαq/11, combine with pathways regulated by BAP1 to control the motility and transmigration of UM cells.

Citing Articles

New Insights into the Exosome-Induced Migration of Uveal Melanoma Cells and the Pre-Metastatic Niche Formation in the Liver.

Ramos R, Vinyals A, Campos-Martin R, Cabre E, Bech J, Vaquero J Cancers (Basel). 2024; 16(17).

PMID: 39272836 PMC: 11394004. DOI: 10.3390/cancers16172977.

Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives.

Kulbay M, Marcotte E, Remtulla R, Lau T, Paez-Escamilla M, Wu K Biomedicines. 2024; 12(8).

PMID: 39200222 PMC: 11352094. DOI: 10.3390/biomedicines12081758.

EHMT2 promotes tumorigenesis in -mutant uveal melanoma ARHGAP29-mediated RhoA pathway.

Li Y, Zhu T, Yang J, Zhang Q, Xu S, Ge S Acta Pharm Sin B. 2024; 14(3):1187-1203.

PMID: 38486999 PMC: 10935147. DOI: 10.1016/j.apsb.2023.12.002.

Septin and actin contributions to endothelial cell-cell junctions and monolayer integrity.

Kim J, Mooren O, Onken M, Cooper J Cytoskeleton (Hoboken). 2022; 80(7-8):228-241.

PMID: 36205643 PMC: 10079785. DOI: 10.1002/cm.21732.

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Lamas N, Martel A, Nahon-Esteve S, Goffinet S, Macocco A, Bertolotto C Cancers (Basel). 2022; 14(1).

PMID: 35008260 PMC: 8749988. DOI: 10.3390/cancers14010096.

References

Clarijs R, Otte-Holler I, Ruiter D, de Waal R . Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci. 2002; 43(4):912-8. View

Acton S, Farrugia A, Astarita J, Mourao-Sa D, Jenkins R, Nye E . Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature. 2014; 514(7523):498-502. PMC: 4235005. DOI: 10.1038/nature13814. View

Bokoch G . Biology of the p21-activated kinases. Annu Rev Biochem. 2003; 72:743-81. DOI: 10.1146/annurev.biochem.72.121801.161742. View

Nolen B, Tomasevic N, Russell A, Pierce D, Jia Z, McCormick C . Characterization of two classes of small molecule inhibitors of Arp2/3 complex. Nature. 2009; 460(7258):1031-4. PMC: 2780427. DOI: 10.1038/nature08231. View

Parri M, Chiarugi P . Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8:23. PMC: 2941746. DOI: 10.1186/1478-811X-8-23. View

Callejo S, Antecka E, Blanco P, Edelstein C, Burnier Jr M . Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye (Lond). 2006; 21(6):752-9. DOI: 10.1038/sj.eye.6702322. View

Onken M, Mooren O, Mukherjee S, Shahan S, Li J, Cooper J . Endothelial monolayers and transendothelial migration depend on mechanical properties of the substrate. Cytoskeleton (Hoboken). 2014; 71(12):695-706. PMC: 4373417. DOI: 10.1002/cm.21203. View

Wyckoff J, Pinner S, Gschmeissner S, Condeelis J, Sahai E . ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol. 2006; 16(15):1515-23. DOI: 10.1016/j.cub.2006.05.065. View

van der Kooij M, Speetjens F, van der Burg S, Kapiteijn E . Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers (Basel). 2019; 11(6). PMC: 6627906. DOI: 10.3390/cancers11060845. View

10.

Dey A, Seshasayee D, Noubade R, French D, Liu J, Chaurushiya M . Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012; 337(6101):1541-6. PMC: 5201002. DOI: 10.1126/science.1221711. View

11.

Chrzanowska-Wodnicka M, Burridge K . Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol. 1996; 133(6):1403-15. PMC: 2120895. DOI: 10.1083/jcb.133.6.1403. View

12.

Yen M, Qi Z, Chen X, Cooper J, Mitra R, Onken M . Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma. BMC Med Genomics. 2018; 11(1):97. PMC: 6219186. DOI: 10.1186/s12920-018-0424-0. View

13.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

14.

Keilholz U, Goldin-Lang P, Bechrakis N, Max N, Letsch A, Schmittel A . Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004; 10(5):1605-12. DOI: 10.1158/1078-0432.ccr-0610-3. View

15.

Collins C, Nelson W . Running with neighbors: coordinating cell migration and cell-cell adhesion. Curr Opin Cell Biol. 2015; 36:62-70. PMC: 4639402. DOI: 10.1016/j.ceb.2015.07.004. View

16.

Maeda M, Hasegawa H, Hyodo T, Ito S, Asano E, Yuang H . ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility. Mol Biol Cell. 2011; 22(20):3840-52. PMC: 3192863. DOI: 10.1091/mbc.E11-04-0364. View

17.

Onken M, Li J, Cooper J . Uveal melanoma cells utilize a novel route for transendothelial migration. PLoS One. 2014; 9(12):e115472. PMC: 4266671. DOI: 10.1371/journal.pone.0115472. View

18.

Schmidt S, Debant A . Function and regulation of the Rho guanine nucleotide exchange factor Trio. Small GTPases. 2014; 5:e29769. PMC: 4114922. DOI: 10.4161/sgtp.29769. View

19.

Van Raamsdonk C, Bezrookove V, Green G, Bauer J, Gaugler L, OBrien J . Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2008; 457(7229):599-602. PMC: 2696133. DOI: 10.1038/nature07586. View

20.

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View